Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study consists of a prospective clinical trial which aims to evaluate the impact of stent insertion for palliation of malignant dysphagia. The main goal being to examine the number of days required following stenting in order to have significant improvement in dysphagia and the length of time that this baseline is maintained. Approximately 100 patients will be prospectively enrolled in this study.
Patients with end stage inoperable esophageal cancer deemed candidates for intraluminal esophageal palliative stent insertion will be prospectively enrolled into the study. Patients with esophageal obstruction or stricture due to other benign causes, tumors obstructing the cervical esophagus, as well as patients with airway-esophageal fistulas will be excluded from the study.
The investigators plan to evaluate the efficacy of intra-esophageal stent insertion to improve malignant dysphagia as a main factor affecting the quality of life in these patients.
| Condition |
|---|
|
Esophageal Cancer |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer (CT0023) |
- improvement of dysphagia post stenting [ Time Frame: 3 months ] [ Designated as safety issue: No ]To assess the effectiveness of esophageal stenting in improving malignant dysphagia and assess the time period relating to this improvement
- Quality of life post stenting [ Time Frame: 3 months ] [ Designated as safety issue: No ]To assess the effectiveness of esophageal stenting in improving quality of life and assess the time period relating to this improvement
| Estimated Enrollment: | 100 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | August 2015 |
| Estimated Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
patients referred to the thoracic clinic or in-patient
Inclusion Criteria:
- All patients with end stage inoperable esophageal cancer deemed candidates for intraluminal esophageal palliative stent insertions.
Exclusion Criteria:
- Inability to consent for the study.
- Patients less than 18 years old.
- Patients with other benign causes of dysphagia and esophageal obstruction or stenosis.
- Patients with malignant or benign airway - esophageal fistulas.
- Patients with cervical esophageal cancer
Contacts and Locations| Canada, Quebec | |
| Centre Hospitalier de l'Université de Montréal | Recruiting |
| Montréal, Quebec, Canada, H2L 4M1 | |
| Contact: Vicky Thiffault, RN, CCRP 514-890-8000 ext 23432 vicky.thiffault.chum@ssss.gouv.qc.ca | |
| Principal Investigator: Moishe Liberman, MD, PhD | |
| Sub-Investigator: Pascal Ferraro, MD | |
| Sub-Investigator: André Duranceau, MD | |
| Sub-Investigator: Jocelyne Martin, MD | |
| Principal Investigator: | Moishe Liberman, MD, PhD | CHUM-Centre Universitaire de Montreal |
More Information
No publications provided
| Responsible Party: | Centre hospitalier de l'Université de Montréal (CHUM) |
| ClinicalTrials.gov Identifier: | NCT01471249 History of Changes |
| Other Study ID Numbers: | CE 11.039 |
| Study First Received: | November 10, 2011 |
| Last Updated: | February 26, 2013 |
| Health Authority: | Canada: Ethics Review Committee Canada: Health Canada |
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):
|
esophageal stenting palliative dysphagia |
Additional relevant MeSH terms:
|
Deglutition Disorders Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Digestive System Diseases Pharyngeal Diseases |
Otorhinolaryngologic Diseases Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms |
ClinicalTrials.gov processed this record on May 23, 2013